ScoreHaematology

CLL International Prognostic Index (CLL-IPI)

Combines genetic, biochemical and clinical data to estimate 5-year survival in chronic lymphocytic leukaemia.

Updated 30 October 2026

When to use it

CLL at diagnosis or before first treatment, to inform prognosis and guide follow-up intensity.

What it needs

  • Altered TP53: del(17p) and/or TP53 mutationYes or no
  • Unmutated IGHVYes or no
  • Serum β2-microglobulin > 3.5 mg/LYes or no
  • Clinical stage Binet B–C or Rai I–IVYes or no
  • Age > 65 yearsYes or no

The points for each answer and the automatic total are in the app.

How to interpret it

CLL-IPI score
ResultInterpretation
≤ 1Low risk (5-year survival ≈ 93 %)
2–3Intermediate risk (5-year survival ≈ 79 %)
4–6High risk (5-year survival ≈ 63 %)
≥ 7Very high risk (5-year survival ≈ 23 %)

Practical tip

It was derived in patients treated with chemotherapy or chemoimmunotherapy; with BTKi or venetoclax it discriminates less well, especially between high and very high risk.

2 more practical tips in the app.

Reference

A support tool for healthcare professionals: it guides and does not replace clinical judgement.

Back to top